IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.05% USD/MXN18.44▼ 0.51% USD/CLP966.96▼ 0.99% USD/COP3,267▲ 4.70% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▲ 2.41% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.19▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.05% USD/MXN 18.45 ▼ 0.42% USD/CLP 966.96 ▼ 0.99% USD/COP 3,267 ▲ 4.70% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▲ 2.41% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.19 ▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Covid-19 Brazil

BioNTech recruits rivals to boost Covid-19 vaccine production

By · · 2 min read

RIO DE JANEIRO, BRAZIL – The maker of the West’s first Covid-19 vaccine is building a new manufacturing alliance that could throw Europe and the rest of the world a lifeline amid a painful shortage of shots and a rebound in infections.

Novartis, Switzerland.
Novartis headquarters building in Switzerland.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The German company that joined with Pfizer to manufacture and distribute its vaccine, has marshaled an alliance of 13 companies, including Novartis, Merck KGaA and Sanofi, in an effort to meet—and perhaps exceed—an ambitious target of making 2 billion doses of vaccine this year.

The European Union has been struggling with a shortage of vaccines as manufacturers, including British-Swedish pharmaceutical firm AstraZeneca, have fallen behind on their delivery pledges to the bloc. The shortage has largely been limited to the EU, which was slower than its Western allies in ordering and approving the vaccines, and it has raised tensions between the bloc and the UK and the US.

BioNTech co-founder and CEO Ugur Sahin told The Wall Street Journal that he realized last fall that the partnership with Pfizer would not be enough to meet global demand. The company’s chief operating officer, Sierk Poetting, added that the experience showed BioNTech the urgency of launching a new alliance in order to meet commitments in Europe and other markets. Through it, about half of the global supply of active ingredient for the covid-19 vaccine will be produced, according to Poetting.

One of the challenges facing the alliance is that BioNTech’s vaccine uses sophisticated new techniques that require few ingredients and expertise. This implies a supply chain vulnerable to export controls that the EU, UK and US have imposed in recent months, according to company officials.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Trump says deportations "might be too tough"”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

In addition, the number of partners, the complexity of the process, and the raw materials needed to produce the company’s vaccine – from DNA to enzymes, salts, sugars, and various lipids – make the supply chain delicate, with many possibilities for supply shortfalls.

Source: Exame

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.